The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma

BACKGROUND: Recent evidence suggested a potential correlation between BMI and the efficacy of immune checkpoint inhibitors in cancer patients. This study aimed to evaluate the prognostic value of the body mass index (BMI) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinyi, Rui, Mengyu, Lin, Chao, Li, Zhi, Wei, Dongliang, Han, Ruxue, Ju, Houyu, Ren, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939135/
https://www.ncbi.nlm.nih.gov/pubmed/35975731
http://dx.doi.org/10.1002/cam4.5152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939135/
https://www.ncbi.nlm.nih.gov/pubmed/35975731
http://dx.doi.org/10.1002/cam4.5152

Ejemplares similares